Eli Lilly’s retatrutide delivered 28.3% average weight loss at 80 weeks in Phase 3, with some patients reaching over 30% at 104 weeks. Analysts at Truist, Wolfe, and RBC stay bullish.
Eli Lilly buys Engage Bio for up to $202M to boost safer gene therapy using non-viral DNA delivery technology.
Novo Nordisk beat expectations as its new weight-loss pill sold fast, boosting sales, prescriptions, and improving its 2026 outlook.
Eli Lilly states that a post-launch report of hepatic failure for Foundayo (orforglipron) is not plausibly linked to the drug. RBC Capital describes it as “statistical background noise.”
Eli Lilly raised profit outlook thanks to strong Zepbound & Mounjaro sales; revenue and earnings beat expectations, stock rose.
Eli Lilly buys Ajax to develop a new pill for rare blood cancers that may work longer and better than current treatments.
